Climacteric Syndrome Clinical Trial
— MonalisaOfficial title:
A Phase III, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Passiflora Incarnata and Isoflavona Combination in the Treatment of Climacteric Symptoms.
The purpose of this study is to evaluate the effects of Passiflora incarnata and Isoflavone combination in relieving the symptoms associated with Climacteric Syndrome.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | March 2015 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 40 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Female amenorrheic for at least one (1) year or surgical menopause since dosage of FSH = 30 mIU / ml; - Age greater than or equal to 40 and less than or equal to 65 years; - Cytological examination colpo held at screening visit, Pap cytology classification with class I and II; - By mammography BI-RADS classification (fourth edition) rated one (1) or two (2) performed at least six (6) months from the time of inclusion in the screening visit or if the research subject does not present a recent survey ; - Line endometrial = 8 mm by transvaginal ultrasound, performed at screening visit, in the case of subjects who have an intact uterus; Exclusion Criteria: - History of severe liver or renal disease at the discretion of the investigator; - Hypertension stage III uncontrolled (SBP = 180 mmHg or DBP = 110 mmHg); - Important cardiovascular disease such as coronary insufficiency or dilated cardiomyopathy advanced; - Using estrogens, progestins, steroid or hormone replacement therapy (HRT) in the last 3 months; - Estrogen-dependent neoplasia; - Thromboembolic disorders for less than one year of screening visit; - Anabolic drugs use or illicit drug use; - Hemoglobin < 10 or > 17 g / dL; - TSH < 0, 550 or > 4, 780 UUI / L; - FT4 < 0.75 ?g / dL or > 1.8 ?g / dL; - Patient that is chronically using MAO inhibitors (MAOIs) or levothyroxine |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Brazil | ISBEM | São Paulo |
Lead Sponsor | Collaborator |
---|---|
Ache Laboratorios Farmaceuticos S.A. |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Menopause Rating Scale - MRS | 104 days | No | |
Secondary | Kuppperman-Blatt index | 90 days | No | |
Secondary | MRS scale | 90 days | No | |
Secondary | MENQOL | 90 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06057896 -
Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
|
||
Not yet recruiting |
NCT06419972 -
Multimodal Program for Climacteric Women
|
N/A | |
Completed |
NCT01275807 -
Effectiveness and Safety of Acupuncture for Climacteric Syndrome in Patients With Breast Cancer
|
Phase 4 | |
Completed |
NCT05846698 -
The Effects of Luo-Bu-Fu-Ke-Bi-RI Pill
|
||
Recruiting |
NCT06136208 -
Pharmacokinetic Aspects of 25-mg Estradiol Pellet in Climacteric Women
|
N/A | |
Completed |
NCT03118908 -
Clinical Evaluation of Effectiveness and Safety of Amberen and Smart B by Women With Climacteric Syndrome
|
N/A |